ATE481101T1 - Verfahren zur behandlung von angstzuständen - Google Patents

Verfahren zur behandlung von angstzuständen

Info

Publication number
ATE481101T1
ATE481101T1 AT04746014T AT04746014T ATE481101T1 AT E481101 T1 ATE481101 T1 AT E481101T1 AT 04746014 T AT04746014 T AT 04746014T AT 04746014 T AT04746014 T AT 04746014T AT E481101 T1 ATE481101 T1 AT E481101T1
Authority
AT
Austria
Prior art keywords
disorder
adenosine
receptor antagonist
treating anxiety
anxiety
Prior art date
Application number
AT04746014T
Other languages
English (en)
Inventor
Hiroshi Kase
Naoki Seno
Shizuo Shiozaki
Minoru Kobayashi
Junya Kase
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Application granted granted Critical
Publication of ATE481101T1 publication Critical patent/ATE481101T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
AT04746014T 2003-06-10 2004-06-10 Verfahren zur behandlung von angstzuständen ATE481101T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50904603P 2003-06-10 2003-06-10
US53279303P 2003-12-24 2003-12-24
PCT/JP2004/008486 WO2004108137A1 (en) 2003-06-10 2004-06-10 A method of treating an anxiety disorder

Publications (1)

Publication Number Publication Date
ATE481101T1 true ATE481101T1 (de) 2010-10-15

Family

ID=33514319

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04746014T ATE481101T1 (de) 2003-06-10 2004-06-10 Verfahren zur behandlung von angstzuständen

Country Status (15)

Country Link
US (2) US8202869B2 (de)
EP (1) EP1631294B1 (de)
JP (1) JP4778894B2 (de)
KR (1) KR20060037252A (de)
CN (1) CN1787821A (de)
AT (1) ATE481101T1 (de)
AU (1) AU2004244906A1 (de)
BR (1) BRPI0411120A (de)
CA (1) CA2528710C (de)
CO (1) CO5640121A2 (de)
DE (1) DE602004029160D1 (de)
EA (1) EA200501924A1 (de)
MX (1) MXPA05013148A (de)
NO (1) NO20055907L (de)
WO (1) WO2004108137A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0306919A (pt) * 2002-01-28 2004-11-09 Kyowa Hakko Kogyo Kk Métodos para reduzir ou suprimir a efetividade adversa da terapia de l-dopa e/ou do agonista da dopamina, e para tratamento moderado de l-dopa, composição para tratamento moderado de l-dopa, método para tratar doença de parkinson e/ou complicações motoras de l-dopa, composição para o tratamento da doença de parkinson, e, métodos para prolongar o tratamento eficaz da doença de parkinson, e para tratar os distúrbios de movimento
US10042980B2 (en) 2005-11-17 2018-08-07 Gearbox Llc Providing assistance related to health
US20070124176A1 (en) * 2005-11-30 2007-05-31 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US20070136092A1 (en) * 2005-11-30 2007-06-14 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
EP2089389A2 (de) 2006-11-01 2009-08-19 Bristol-Myers Squibb Company Heterocyclische verbindungen als modulatoren der glucocorticoidrezeptor,- ap1- und/oder nf-kappa-b-aktivität
MX2010000938A (es) * 2007-07-23 2010-07-01 Synosia Therapeutics Inc Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del ácido 4-hidroxi-4-metil-piperidin-1-carboxílico para el tratamiento del trastorno por estrés postraumático.
UA113383C2 (xx) 2009-09-02 2017-01-25 Терапевтичний агент для лікування тривожних розладів
UA110097C2 (uk) 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою
US8609162B2 (en) 2012-10-04 2013-12-17 Invivo Beverages Llc Integrated neuromodulation system for mood enhancement of a living human subject
CN105770563A (zh) * 2016-04-22 2016-07-20 孙建 一种治疗焦虑症的中药制剂及其制备方法
US20190292188A1 (en) 2018-02-27 2019-09-26 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
MA52940A (fr) 2018-05-18 2021-04-28 Incyte Corp Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
CN113166153B (zh) 2018-07-05 2024-11-01 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2022167778A1 (en) 2021-02-02 2022-08-11 Haiku Therapeutics Ltd Ebselen as adenosine receptor modulator
KR102594242B1 (ko) 2023-01-10 2023-10-27 주식회사 웨이센 디지털 표현형 특징을 이용한 사회 불안장애 분석방법 및 장치
KR102567684B1 (ko) 2023-01-10 2023-08-18 주식회사 웨이센 디지털 표현형 특징을 이용한 사회 불안장애 분석방법 및 장치

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3781080T2 (de) * 1986-09-30 1992-12-24 Ciba Geigy Ag 2-substituierte-e-kondensierte(1,2,4)triazolo-(1,5-c)pyrimidine, pharmazeutische zubereitungen und ihre verwendung.
US5047534A (en) * 1990-03-26 1991-09-10 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
US5484920A (en) 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
JP2928386B2 (ja) 1992-07-08 1999-08-03 協和醗酵工業株式会社 うつ病治療剤
DE69834500T2 (de) 1997-09-05 2007-05-03 Kyowa Hakko Kogyo Co., Ltd. Xanthinderivative zur behandlung von hirnischämie
AU756144B2 (en) * 1998-09-22 2003-01-02 Kyowa Hakko Kogyo Co. Ltd. (1,2,4)triazolo(1,5-c)pyrimidine derivatives
EP1177797A1 (de) * 1999-05-12 2002-02-06 Fujisawa Pharmaceutical Co., Ltd. Neue verwendung
MY132006A (en) * 2000-05-26 2007-09-28 Schering Corp ADENOSINE A2a RECEPTOR ANTAGONISTS
WO2003022283A1 (en) * 2001-09-13 2003-03-20 Schering Corporation Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
HUP0401777A3 (en) * 2001-10-15 2008-06-30 Schering Corp 3h-[1,2,4]triazolo[5,1-i]purin-5-yl amines as adenosine a2a receptor antagonists and pharmaceutical compositions containing the compounds
US20030119831A1 (en) * 2001-11-20 2003-06-26 Hartz Richard A. 3,7-dihydro-purine-2,6-dione derivatives as CRF receptor ligands
US20060128694A1 (en) * 2002-12-19 2006-06-15 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders

Also Published As

Publication number Publication date
EP1631294B1 (de) 2010-09-15
EP1631294A1 (de) 2006-03-08
EA200501924A1 (ru) 2006-06-30
US8592420B2 (en) 2013-11-26
CO5640121A2 (es) 2006-05-31
JP4778894B2 (ja) 2011-09-21
CA2528710A1 (en) 2004-12-16
NO20055907L (no) 2005-12-13
DE602004029160D1 (de) 2010-10-28
BRPI0411120A (pt) 2006-07-18
WO2004108137A1 (en) 2004-12-16
CA2528710C (en) 2012-04-17
KR20060037252A (ko) 2006-05-03
JP2006527264A (ja) 2006-11-30
MXPA05013148A (es) 2006-03-17
US20120232089A1 (en) 2012-09-13
AU2004244906A1 (en) 2004-12-16
US20060281770A1 (en) 2006-12-14
CN1787821A (zh) 2006-06-14
US8202869B2 (en) 2012-06-19

Similar Documents

Publication Publication Date Title
ATE481101T1 (de) Verfahren zur behandlung von angstzuständen
CY1120384T1 (el) Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
ATE451376T1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
ATE464303T1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
ATE542803T1 (de) Verfahren zur herstellung von dihydrochinazolinen
ATE541859T1 (de) Humane anti-interferon-gamma-antikörper und verfahren zu ihrer verwendung
DE69939312D1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
EA200700708A1 (ru) Мемантин для лечения расстройств поведения детского возраста
ATE478661T1 (de) Verfahren zur reduzierung der angiogenese
DE602004012578D1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
TW200507840A (en) Method of treating multiple myeloma
DE602006017574D1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
DE602006008583D1 (de) Stabile kristalline form von bifeprunoxmesylat, dosierungsformen davon und verfahren zu deren verwendung
ATE446299T1 (de) Verfahren zur herstellung von 7-ethyl-10- hydroxycamptothecin
DE60239450D1 (de) Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonisten
EA200801081A1 (ru) Способы лечения расстройств центральной нервной системы комбинацией малых доз эсциталопрама и бупропиона
ATE453386T1 (de) Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten
DE602004022423D1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz
ATE342372T1 (de) Verfahren zur herstellung von d-pantothensäure und/oder deren salze als zusatz zu tierfuttermitteln
EA200501052A1 (ru) Способ лечения поведенческих расстройств

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties